Article citationsMore>>

Borowitz, D., Robinson, K., Rosenfeld, M., Davis, S.D., Sabadosa, K.A., Spear, S.L., Michel, S.H., Parad, R.B., White, T.B., Farell, P.M., Marshall, B.C. and Accurso, F.J. (2009) Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. The Journal of Pediatrics, 155, S73-S93.
https://doi.org/10.1016/j.jpeds.2009.09.001

has been cited by the following article:

• TITLE: The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus Non-CF Patients)

  AUTHORS: Heba A. Ali, Thrwat E. Deraz, Dina A. Mohamed, Menna Z. Mahmoud

  KEYWORDS: Cystic Fibrosis, Non-CF Bronchiectasis, Vitamin D3 Supplementation, Exacerbation, FEV1

  JOURNAL NAME: Open Journal of Pediatrics, Vol.10 No.3, September 25, 2020

  ABSTRACT: Objective: To determine and compare the effect of vitamin D3 supplementation on modifying the disease severity in cystic fibrosis (CF) and non-CF bronchiectasis pediatric patients. Methods: A randomized clinical trial evaluating the role of oral vitamin D3 supplementation for six months, was performed in forty patients with CF and non-CF bronchiectasis under the age of 18 years with vitamin D deficiency or insufficiency. The primary outcome was to reach the sufficient Vitamin D level, the secondary outcome was to reevaluate bronchiectasis severity by following up the frequency, severity of pulmonary exacerbations and lung function after vitamin D3 supplementation. Results: Forty patients completed the trial. The percentage of improvement of vitamin D level after vitamin D3 supplementation for six months was significantly higher in CF (88.3%) than non-CF bronchiectasis patients (59.82%) (P = 0.03). Additionally, moderate to severe pulmonary exacerbations significantly decreased by more than 60%, 45% (P = 0.001, 0.005) and frequent exacerbations decreased by 15%, 10% (P = 0.327, 0.490), while the forced expiratory volume in 1 (FEV1) significantly increased by 17% and 15% in non CF bronchiectasis and CF patients respectively (p 0.001). Conclusions: Vitamin D3 therapy was effective in decreasing the frequency and severity of pulmonary exacerbations and preserving lung function. Thereby, improving the disease severity even more in non-CF bronchiectasis than CF patients.